# A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

> **NCT02812875** · PHASE1 · COMPLETED · sponsor: **Curis, Inc.** · enrollment: 71 (actual)

## Conditions studied

- Advanced Solid Tumors or Lymphomas

## Interventions

- **DRUG:** CA-170

## Key facts

- **NCT ID:** NCT02812875
- **Lead sponsor:** Curis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2020-05-07
- **Final completion:** 2020-05-07
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2020-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02812875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02812875, "A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02812875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*